STOK Quote, Financials, Valuation and Earnings

iBio has a net margin of -540.05% compared to Stoke Therapeutics's net margin of -4444.57%. Stoke Therapeutics's return on equity of -55.64% beat iBio's return on equity of -148.3%.

Stoke Therapeutics has a consensus price target of $22.29, signalling upside risk potential of 103.99%. On the other hand iBio has an analysts' consensus of -- which suggests that it could grow by 46.94%. Given that Stoke Therapeutics has higher upside potential than iBio, analysts believe Stoke Therapeutics is more attractive than iBio.

Stoke Therapeutics has a beta of 0.953, which suggesting that the stock is 4.669% less volatile than S&P 500. In comparison iBio has a beta of -3.266, suggesting its less volatile than the S&P 500 by 426.584%.

Stoke Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iBio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stoke Therapeutics pays -- of its earnings as a dividend. iBio pays out -- of its earnings as a dividend.

Stoke Therapeutics quarterly revenues are $4.9M, which are larger than iBio quarterly revenues of $175K. Stoke Therapeutics's net income of -$26.4M is lower than iBio's net income of -$4M. Notably, Stoke Therapeutics's price-to-earnings ratio is -- while iBio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stoke Therapeutics is 33.49x versus -- for iBio. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -540.05% compared to Stoke Therapeutics's net margin of -49.65%. Stoke Therapeutics's return on equity of -55.64% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Stoke Therapeutics has a consensus price target of $22.29, signalling upside risk potential of 103.99%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $7.30 which suggests that it could grow by 519.8%. Given that NovaBay Pharmaceuticals has higher upside potential than Stoke Therapeutics, analysts believe NovaBay Pharmaceuticals is more attractive than Stoke Therapeutics.

Stoke Therapeutics has a beta of 0.953, which suggesting that the stock is 4.669% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.646, suggesting its less volatile than the S&P 500 by 35.372%.

Stoke Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stoke Therapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Stoke Therapeutics quarterly revenues are $4.9M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Stoke Therapeutics's net income of -$26.4M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Stoke Therapeutics's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stoke Therapeutics is 33.49x versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -540.05% compared to Stoke Therapeutics's net margin of -2357.27%. Stoke Therapeutics's return on equity of -55.64% beat Palatin Technologies's return on equity of --.

Stoke Therapeutics has a consensus price target of $22.29, signalling upside risk potential of 103.99%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1431.53%. Given that Palatin Technologies has higher upside potential than Stoke Therapeutics, analysts believe Palatin Technologies is more attractive than Stoke Therapeutics.

Stoke Therapeutics has a beta of 0.953, which suggesting that the stock is 4.669% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.929%.

Stoke Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stoke Therapeutics pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Stoke Therapeutics quarterly revenues are $4.9M, which are larger than Palatin Technologies quarterly revenues of $350K. Stoke Therapeutics's net income of -$26.4M is lower than Palatin Technologies's net income of -$7.8M. Notably, Stoke Therapeutics's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stoke Therapeutics is 33.49x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -540.05% compared to Stoke Therapeutics's net margin of --. Stoke Therapeutics's return on equity of -55.64% beat Theriva Biologics's return on equity of --.

Stoke Therapeutics has a consensus price target of $22.29, signalling upside risk potential of 103.99%. On the other hand Theriva Biologics has an analysts' consensus of -- which suggests that it could grow by 5071.43%. Given that Theriva Biologics has higher upside potential than Stoke Therapeutics, analysts believe Theriva Biologics is more attractive than Stoke Therapeutics.

Stoke Therapeutics has a beta of 0.953, which suggesting that the stock is 4.669% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.234, suggesting its more volatile than the S&P 500 by 23.367%.

Stoke Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stoke Therapeutics pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Stoke Therapeutics quarterly revenues are $4.9M, which are larger than Theriva Biologics quarterly revenues of --. Stoke Therapeutics's net income of -$26.4M is lower than Theriva Biologics's net income of -$7.7M. Notably, Stoke Therapeutics's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stoke Therapeutics is 33.49x versus 1.59x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.